Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 19, Issue 41, 2013, Pages 7024-7031

  Li, Meng ^a   Shen, Zhe ^a   Li, You Ming ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cytokines; Helicobacter pylori; Inflammation; Insulin resistance; Nonalcoholic fatty liver disease

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; FETUIN A; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY RESPONSE; DISEASE ASSOCIATION; DISEASE COURSE; DNA SEQUENCE; GENE EXPRESSION; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE MUCOSA PERMEABILITY; LIPID METABOLISM; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SEROLOGY; CHRONIC INFLAMMATION; PATHOGENESIS;

CYTOKINES; HELICOBACTER PYLORI; INFLAMMATION; INSULIN RESISTANCE; NONALCOHOLIC FATTY LIVER DISEASE;

ANIMALS; ANTI-BACTERIAL AGENTS; ENERGY METABOLISM; FATTY LIVER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INSULIN RESISTANCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84887560969     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i41.7024     Document Type: Review

References (101)

1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-741 [PMID: 9336670]
2. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A casecontrol study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med 2005; 165: 1552-1555 [PMID: 16009873 DOI: 10.1001/ archinte.165.13.1552]
3. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-490 [PMID: 16847081]
4. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis 1993; 168: 219-221 [PMID: 8515114]
5. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-323 [PMID: 18166359 DOI: 10.1053/j.gastro.2007.11.009]
6. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012; 30: 677-706 [PMID: 22224761 DOI: 10.1146/annurevimmunol-020711-075008]
7. Takuma Y. Helicobacter pylori infection and liver diseases. Gan To Kagaku Ryoho 2011; 38: 362-364 [PMID: 21403438]
8. Pellicano R, Ménard A, Rizzetto M, Mégraud F. Helicobacter species and liver diseases: association or causation? Lancet Infect Dis 2008; 8: 254-260 [PMID: 18353266 DOI: 10.1016/ s1473-3099(08)70066-5]
9. Pellicano R, Fagoonee S, Rizzetto M, Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol 2003; 29: 351-359 [PMID: 14636044 DOI: 10.1080/713608015]
10. Abdel-Hady H, Zaki A, Badra G, Lotfy M, Selmi C, Giorgini A, El-Sayed M, Badr R. Helicobacter pylori infection in hepatic encephalopathy: Relationship to plasma endotoxins and blood ammonia. Hepatol Res 2007; 37: 1026-1033 [PMID: 17610507 DOI: 10.1111/j.1872-034X.2007.00146.x]
11. Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat 2012; 19: 473-479 [PMID: 22676359 DOI: 10.1111/ j.1365-2893.2011.01567.x]
12. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48 Suppl 1: S104-S112 [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009]
13. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19: 5169-5176 [PMID: 23394091]
14. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]
15. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865]
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474 [PMID: 10484010]
17. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-171 [PMID: 20078219 DOI: 10.1146/annurevpathol-121808-102132]
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461]
19. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129: 375-378 [PMID: 16012969]
20. Larrain S, Rinella ME. A myriad of pathways to NASH. Clin Liver Dis 2012; 16: 525-548 [PMID: 22824479 DOI: 10.1016/ j.cld.2012.05.009]
21. McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, Deaciuc I. Mechanisms of non-alcoholic steatohepatitis. Alcohol 2004; 34: 67-79 [PMID: 15670668 DOI: 10.1016/ j.alcohol.2004.07.007]
22. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis 2012; 32: 14-21 [PMID: 22418884 DOI: 10.1055/s-0032-1306422]
23. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41 [PMID: 11296694]
24. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995; 44: 369-374 [PMID: 7698502]
25. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353 [PMID: 15166226 DOI: 10.1074/jbc. M313478200]
26. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350 [PMID: 12540784 DOI: 10.1053/jhep.2003.50048]
27. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011; 16: 79-88 [PMID: 21435084]
28. Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, Dumlu S, Turet S. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur J Gastroenterol Hepatol 2008; 20: 33-36 [PMID: 18090988 DOI: 10.1097/MEG.0b013e3282efa4f2]
29. Battles JK, Williamson JC, Pike KM, Gorelick PL, Ward JM, Gonda MA. Diagnostic assay for Helicobacter hepaticus based on nucleotide sequence of its 16S rRNA gene. J Clin Microbiol 1995; 33: 1344-1347 [PMID: 7542270]
30. Monstein H, Nikpour-Badr S, Jonasson J. Rapid molecular identification and subtyping of Helicobacter pylori by pyrosequencing of the 16S rDNA variable V1 and V3 regions. FEMS Microbiol Lett 2001; 199: 103-107 [PMID: 11356575]
31. Pirouz T, Zounubi L, Keivani H, Rakhshani N, Hormazdi M. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci 2009; 54: 1456-1459 [PMID: 18975076 DOI: 10.1007/s10620-008-0522-5]
32. Polyzos SA, Kountouras J, Papatheodorou A, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, Anastasiadou K, Terpos E. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013; 62: 121-126 [PMID: 22841522 DOI: 10.1016/j.metabol.2012.06.007]
33. Doǧan Z, Filik L, Ergül B, Sarikaya M, Akbal E. Association between Helicobacter pylori and liver-to-spleen ratio: a randomized-controlled single-blind study. Eur J Gastroenterol Hepatol 2013; 25: 107-110 [PMID: 23013624 DOI: 10.1097/ MEG.0b013e3283590c10]
34. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379 [PMID: 11826411 DOI: 10.1053/jhep.2002.30692]
35. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10 [PMID: 10869282]
36. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004; 113: 321-333 [PMID: 14755326 DOI: 10.1172/jci20925]
37. Huang FY, Chan AO, Rashid A, Wong DK, Cho CH, Yuen MF. Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1β activation of nitric oxide production in gastric cancer cells. Cancer 2012; 118: 4969-4980 [PMID: 22415887]
38. Arslan E, Atilgan H, Yavaşoǧlu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med 2009; 20: 695-697 [PMID: 19818289 DOI: 10.1016/j.ejim.2009.07.013]
39. Vaarala O, Yki-Järvinen H. Diabetes: Should we treat infection or inflammation to prevent T2DM? Nat Rev Endocrinol 2012; 8: 323-325 [PMID: 22430880]
40. Jeon CY, Haan MN, Cheng C, Clayton ER, Mayeda ER, Miller JW, Aiello AE. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35: 520-525 [PMID: 22279028 DOI: 10.2337/dc11-1043]
41. Eshraghian A, Pellicano R. Comment on: Jeon et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35: 520-525. Diabetes Care 2013; 36: e20 [PMID: 23264304 DOI: 10.2337/dc12-0570]
42. Kantartzis K, Machann J, Schick F, Fritsche A, Häring HU, Stefan N. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 2010; 53: 882-889 [PMID: 20099057 DOI: 10.1007/s00125-010-1663-6]
43. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63 [PMID: 10857969]
44. Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA, Eshraghian K, Taghavi SA. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 2009; 54: 1966-1970 [PMID: 19009348 DOI: 10.1007/s10620-008-0557-7]
45. Naja F, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M, Sibai A, Gali-Muhtasib H. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter 2012; 17: 444-451 [PMID: 23066847 DOI: 10.1111/j.1523-5378.2012.00970.x]
46. Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 2003; 376: 135-145 [PMID: 12943536 DOI: 10.1042/ bj20030676]
47. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279-1285 [PMID: 22842477]
48. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, Grunberger G. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993; 7: 1445-1455 [PMID: 7906861]
49. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, Inoue M, Suehiro T, Terada Y. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb 2010; 17: 925-933 [PMID: 20543523]
50. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57: 2762-2767 [PMID: 18633113 DOI: 10.2337/db08-0538]
51. Sun Q, Cornelis MC, Manson JE, Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 2013; 62: 49-55 [PMID: 22923470 DOI: 10.2337/db12-0372]
52. Kebapcilar L, Bilgir O, Cetinkaya E, Akyol M, Bilgir F, Bozkaya G. The effect of Helicobacter pylori eradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-a levels. Clinics (Sao Paulo) 2010; 65: 799-802 [PMID: 20835558]
53. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 1998; 95: 14429-14434 [PMID: 9826717]
54. Manolakis AC, Tiaka EK, Kapsoritakis AN, Georgoulias P, Tsiopoulos F, Valotassiou V, Potamianos SP. Increased fetuin A levels in Helicobacter pylori infection: a missing link between H. pylori and insulin resistance? Diabetologia 2011; 54: 472-474 [PMID: 21116603 DOI: 10.1007/s00125-010-1995-2]
55. Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab 2012; 97: 4717-4723 [PMID: 23066121 DOI: 10.1210/jc.2012-2414]
56. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008; 3: e1765 [PMID: 18335040 DOI: 10.1371/journal.pone.0001765]
57. Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-948 [PMID: 1881419 DOI: 10.1056/nejm199109263251307]
58. Straubinger RK, Greiter A, McDonough SP, Gerold A, Scanziani E, Soldati S, Dailidiene D, Dailide G, Berg DE, Simpson KW. Quantitative evaluation of inflammatory and immune responses in the early stages of chronic Helicobacter pylori infection. Infect Immun 2003; 71: 2693-2703 [PMID: 12704144]
59. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32: 1473-1477 [PMID: 1773951]
60. Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter 2010; 15 Suppl 1: 14-20 [PMID: 21054648 DOI: 10.1111/j.1523-5378.2010.00781.x]
61. Suganuma M, Kuzuhara T, Yamaguchi K, Fujiki H. Carcinogenic role of tumor necrosis factor-alpha inducing protein of Helicobacter pylori in human stomach. J Biochem Mol Biol 2006; 39: 1-8 [PMID: 16466631]
62. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009; 119: 2475-2487 [PMID: 19729845 DOI: 10.1172/ jci38605]
63. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801 [PMID: 16823477 DOI: 10.1172/jci29069]
64. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137 [PMID: 11916936]
65. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102 [PMID: 10393687]
66. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91 [PMID: 7678183]
67. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-26058 [PMID: 8253716]
68. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54 [PMID: 15239085 DOI: 10.1002/hep.20280]
69. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-194 [PMID: 15239102 DOI: 10.1002/hep.20283]
70. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesityinduced insulin resistance. Science 1996; 271: 665-668 [PMID: 8571133]
71. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alphainduced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 971-976 [PMID: 8995390]
72. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol 2012; 13: 383-396 [PMID: 22617471 DOI: 10.1038/nrm3351]
73. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69 [PMID: 22064361 DOI: 10.1016/j.free radbiomed.2011.10.003]
74. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011; 53: 131-140 [PMID: 21629127 DOI: 10.1097/ MPG.0b013e31822578db]
75. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12: 695-708 [PMID: 21772278]
76. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190 [PMID: 15685173]
77. Savvidou S, Hytiroglou P, Orfanou-Koumerkeridou H, Panderis A, Frantzoulis P, Goulis J. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol 2009; 43: 765-772 [PMID: 19525862 DOI: 10.1097/MCG.0b013e31819e9048]
78. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, Pedersen AA, Kalthoff C, Tullin S, Sams A, Summer R, Walsh K. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010; 285: 6153-6160 [PMID: 20028977 DOI: 10.1074/jbc.M109.088708]
79. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMPdependent pathway. Circulation 2000; 102: 1296-1301 [PMID: 10982546]
80. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 [PMID: 12840063 DOI: 10.1172/jci17797]
81. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184 [PMID: 15239101]
82. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008; 34: 649-657 [PMID: 19195626]
83. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292 [PMID: 9389420 DOI: 10.1007/s001250050822]
84. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198 [PMID: 15685170]
85. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48: 1-26 [PMID: 18824034 DOI: 10.1016/j.plipres.2008.08.001]
86. Satoh H, Saijo Y, Yoshioka E, Tsutsui H. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb 2010; 17: 1041-1048 [PMID: 20610892]
87. Akbas HS, Basyigit S, Suleymanlar I, Kemaloglu D, Koc S, Davran F, Demir I, Suleymanlar G. The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects. Lipids Health Dis 2010; 9: 92 [PMID: 20804546 DOI: 10.1186/1476-511x-9-92]
88. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010; 15 Suppl 1: 60-68 [PMID: 21054655]
89. Abenavoli L, Milic N, De Lorenzo A, Luzza F. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine 2013; 43: 65-67 [PMID: 22740094 DOI: 10.1007/s12020-012-9731-y]
90. Korponay-Szabó IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, Fésüs L, Mäki M. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004; 53: 641-648 [PMID: 15082580]
91. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141: 1220-1230, 1230. e1-3 [PMID: 21726511 DOI: 10.1053/j.gastro.2011.06.063]
92. Gäbele E, Dostert K, Hofmann C, Wiest R, Schölmerich J, Hellerbrand C, Obermeier F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011; 55: 1391-1399 [PMID: 21703208 DOI: 10.1016/j.jhep.2011.02.035]
93. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
94. Abenavoli L, Arena V, Giancotti F, Vecchio FM, Abenavoli S. Celiac disease, primary biliary cirrhosis and helicobacter pylori infection: one link for three diseases. Int J Immunopathol Pharmacol 2010; 23: 1261-1265 [PMID: 21244776]
95. Nilsson I, Lindgren S, Eriksson S, Wadström T. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease. Gut 2000; 46: 410-414 [PMID: 10673306]
96. Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, Ram M, Youinou P, Shoenfeld Y. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. Exp Mol Pathol 2012; 93: 386-390 [PMID: 23022373 DOI: 10.1016/j.yexmp.2012.09.012]
97. Neuberger J. Primary biliary cirrhosis. Lancet 1997; 350: 875-879 [PMID: 9310614 DOI: 10.1016/s0140-6736(97)05419-6]
98. Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012; 9: 152-161 [PMID: 22249728 DOI: 10.1038/nrgastro.2011.273]
99. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, Louvet A, Dharancy S, Cocq P, Jany T, Boitard J, Deltenre P, Romon M, Pattou F. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006; 130: 1617-1624 [PMID: 16697725 DOI: 10.1053/j.gastro.2006.02.024]
100. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 396-406 [PMID: 18956296 DOI: 10.1055/ s-0028-1091984]
101. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192 [PMID: 11266382 DOI: 10.1053/gast.2001.23256]